COVID 19 therapies and anti-cancer drugs: A systematic review of recent literature.
Antiviral therapy
Cancer
Coronavirus disease SARS-CoV-2 (COVID-19)
Drug-interactions
Management
Journal
Critical reviews in oncology/hematology
ISSN: 1879-0461
Titre abrégé: Crit Rev Oncol Hematol
Pays: Netherlands
ID NLM: 8916049
Informations de publication
Date de publication:
Aug 2020
Aug 2020
Historique:
received:
15
04
2020
revised:
05
05
2020
accepted:
14
05
2020
pubmed:
17
6
2020
medline:
16
7
2020
entrez:
17
6
2020
Statut:
ppublish
Résumé
It is reasonable to think that cancer patients undergoing chemotherapy, targeted therapy or immunotherapy could have a more aggressive course if positive for Coronavirus disease CoV-2 (COVID- 19). We conducted a literature review on https://www.ncbi.nlm.nih.gov/pubmed/, https://scholar.google.com, www.arxiv.org, www.biorxiv.org, of all articles published using the keywords COVID-19 therapy or treatment and cancer until May 2, 2020. A total of 205 articles were identified and 53 were included in this review. We describe the ongoing COVID-19 therapies that should be known by oncologists and highlight the potential interactions with antineoplastic drugs, commonly used in clinical practice. The main drug interactions were found with tocilizumab, ruxolitinib and colchicine. The literature provides an inconclusive picture on potential preferred treatments for COVID-19 and their interactions with antineoplastic agents. Future clinical trials are needed to better understand the interactions between different drugs in the context of COVID-19 pandemic.
Sections du résumé
BACKGROUND
BACKGROUND
It is reasonable to think that cancer patients undergoing chemotherapy, targeted therapy or immunotherapy could have a more aggressive course if positive for Coronavirus disease CoV-2 (COVID- 19).
METHODS
METHODS
We conducted a literature review on https://www.ncbi.nlm.nih.gov/pubmed/, https://scholar.google.com, www.arxiv.org, www.biorxiv.org, of all articles published using the keywords COVID-19 therapy or treatment and cancer until May 2, 2020. A total of 205 articles were identified and 53 were included in this review.
RESULTS
RESULTS
We describe the ongoing COVID-19 therapies that should be known by oncologists and highlight the potential interactions with antineoplastic drugs, commonly used in clinical practice. The main drug interactions were found with tocilizumab, ruxolitinib and colchicine.
CONCLUSIONS
CONCLUSIONS
The literature provides an inconclusive picture on potential preferred treatments for COVID-19 and their interactions with antineoplastic agents. Future clinical trials are needed to better understand the interactions between different drugs in the context of COVID-19 pandemic.
Identifiants
pubmed: 32544802
pii: S1040-8428(20)30129-3
doi: 10.1016/j.critrevonc.2020.102991
pmc: PMC7239789
pii:
doi:
Substances chimiques
Antineoplastic Agents
0
Types de publication
Journal Article
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
102991Informations de copyright
Copyright © 2020 Elsevier B.V. All rights reserved.
Références
Eur J Pharm Sci. 2019 Apr 1;131:58-68
pubmed: 30690185
Clin Infect Dis. 2020 Jul 28;71(15):769-777
pubmed: 32176772
JAMA. 2020 May 19;323(19):1897-1898
pubmed: 32208486
J Gastroenterol Hepatol. 2020 Sep;35(9):1477-1487
pubmed: 32246857
N Engl J Med. 2011 May 26;364(21):1995-2005
pubmed: 21612468
Clin Adv Hematol Oncol. 2018 May;16(5):364-374
pubmed: 29851932
Nat Commun. 2020 Jan 10;11(1):222
pubmed: 31924756
Ann Oncol. 2018 May 1;29(5):1334-1335
pubmed: 29788168
Acta Oncol. 2018 May;57(5):705-708
pubmed: 29171332
Blood Adv. 2020 Apr 14;4(7):1307-1310
pubmed: 32243501
Int J Oncol. 2015 Apr;46(4):1551-9
pubmed: 25625841
ESMO Open. 2020 Apr;5(2):e000765
pubmed: 32245904
Int J Antimicrob Agents. 2020 Jul;56(1):105949
pubmed: 32205204
Oncologist. 2020 Jun;25(6):e936-e945
pubmed: 32243668
J Natl Compr Canc Netw. 2020 Mar 20;:1-4
pubmed: 32197238
Ann Oncol. 2020 Jul;31(7):894-901
pubmed: 32224151
Neuro Oncol. 2020 Apr 11;:
pubmed: 32277236
Radiother Oncol. 2020 Jun;147:84-85
pubmed: 32247204
Radiat Oncol. 2020 Apr 7;15(1):74
pubmed: 32264908
Drug Saf. 2018 Oct;41(10):919-931
pubmed: 29858838
Ecancermedicalscience. 2020 Apr 01;14:ed97
pubmed: 32269597
Lancet. 2020 Apr 11;395(10231):1225-1228
pubmed: 32178769
Clin Oncol (R Coll Radiol). 2020 May;32(5):279-281
pubmed: 32241520
Adv Radiat Oncol. 2020 Apr 01;5(4):659-665
pubmed: 32292839
J Thromb Haemost. 2020 May;18(5):1020-1022
pubmed: 32239799
Diabetes Res Clin Pract. 2020 Apr;162:108125
pubmed: 32224164
J Infect. 2020 Jul;81(1):e1-e5
pubmed: 32171872
Lancet Haematol. 2020 Apr;7(4):e351-e352
pubmed: 32220344
Colorectal Dis. 2020 Jun;22(6):625-634
pubmed: 32233064
Ecancermedicalscience. 2020 Mar 30;14:1023
pubmed: 32256706
Nat Rev Clin Oncol. 2020 May;17(5):268-270
pubmed: 32242095
J Korean Med Sci. 2020 Feb 17;35(6):e79
pubmed: 32056407
Int Immunopharmacol. 2020 Jun;83:106455
pubmed: 32272396
Lancet Oncol. 2020 Apr;21(4):467
pubmed: 32240603
Lancet Infect Dis. 2020 Apr;20(4):400-402
pubmed: 32113509
AIDS. 2018 Nov 13;32(17):2640-2642
pubmed: 30379691
Lancet Oncol. 2020 Mar;21(3):335-337
pubmed: 32066541
Clin Cancer Res. 2015 Mar 1;21(5):950-4
pubmed: 25601959
JAMA Otolaryngol Head Neck Surg. 2020 Jun 1;146(6):579-584
pubmed: 32232423
Immunotherapy. 2020 Apr;12(5):269-273
pubmed: 32212881
J Gynecol Obstet Hum Reprod. 2020 Jun;49(6):101729
pubmed: 32247066
JAMA. 2015 Apr 28;313(16):1657-65
pubmed: 25919529
Clin Rev Allergy Immunol. 2020 Dec;59(3):334-351
pubmed: 32222877
Integr Cancer Ther. 2020 Jan-Dec;19:1534735420912811
pubmed: 32178547
Int J Antimicrob Agents. 2020 Jun;55(6):105948
pubmed: 32201353